Skip to main content

Matthew J. Gardella

Member

[email protected]

+1.617.348.1735

Share:

Matt represents publicly traded companies and companies on their way to an IPO, especially in capital-raising transactions and mergers and acquisitions.  He handles IPOs, private placements, follow-on offerings and debt offerings for companies whose business depends on well-executed access to the capital markets.  With respect to M&A, Matt regularly advises companies, boards of directors, special committees, investment banks and investors in both buy and sell-side M&A, other strategic transactions and defensive measures.  In addition, Matt counsels public companies on a broad range of corporate, securities and business-related matters, including fiduciary duties, corporate governance and SEC reporting. He is consistently recognized by the publication Best Lawyers in America for corporate governance and other areas. Matt has served as outside general counsel for publicly traded clients in a broad range of industries, especially life sciences, technology and media/telecommunications.

Education

  • Boston University School of Law (JD)
  • Dartmouth College (BA)

Experience

Mergers & Acquisitions

  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) in its $11.5 billion sale to Thermo Fisher Scientific, Inc. (NYSE: TMO)
  • Netsmart's acquisition of healthcare advisory firm, McBee Associates 
  • Synlogic, Inc. in its merger with Mirna Therapeutics, Inc. (Nasdaq: MIRN)
  • Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)
  • Synta Pharmaceuticals (Nasdaq: SNTA) in its merger with Madrigal Pharmaceuticals
  • Atlantic Tele-Network (Nasdaq: ATNI) in its $145 million acquisition of Innovative Group
  • Netsmart Technologies, Inc. in multiple acquisitions, including of HealthMEDX; Lavender & Wyatt Systems; Trend Consulting Services; Defran Systems; and Sequest Technologies
  • Essilor International SA in its $270 million acquisition of Costa Inc. (Nasdaq: ATX)
  • FGX International in its acquisition of Stylemark
  • ASSA ABLOY AB in its $80 million acquisition of LaserCard Corporation (Nasdaq: LCRD)
  • ABRY Partners, a private equity firm, in its $1.3 billion acquisition of RCN Corporation (Nasdaq: RCNI)
  • Cequent Pharmaceuticals in its sale to Marina Biotech, Inc. (Nasdaq: MRNAD), formerly known as MDRNA, Inc.
  • Dynasil Corporation of America (Nasdaq: DYSL) in its acquisition of Hilger Crystal Limited, a U.K. subsidiary of Newport Corp. (Nasdaq: NEWP)
  • Management team of Netsmart Technologies, Inc. in connection with the acquisition of Netsmart by private equity firm, Genstar Capital, including terms of management’s “roll-over” and co-investment arrangements and related employment and compensation arrangements
  • Takeda Pharmaceutical Company Limited (TSE:4502) in its $8.8 billion acquisition of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM), one of the largest foreign acquisitions by a Japanese company, the largest by a Japanese company in the pharmaceutical industry and IDD magazine‘s “Healthcare Deal of the Year” in 2008
  • Lane, Berry & Co. International LLC in its sale to Raymond James Financial, Inc.
  • Netsmart Technologies, Inc. in its acquisition of the assets of the Therapist Helper Division from Nightingale Informatix Corporation (TSX-V:  NGH)
  • XIUS – bcgi in its sale of substantially all of its interests in its Israeli subsidiary, Puresight Technologies Limited
  • Boston Communications Group, Inc. (Nasdaq: BCGI) in its $65 million merger with Megasoft Limited
  • Helix Technology Corporation (Nasdaq: HELX) in its agreement to merge with Brooks Automation in a $450 million stock swap

Securities Offerings

  • Spero Therapeutics, Inc. in its $75 million follow-on offering, its $10 million registered direct offering and its $30 million rights offering
  • Molecular Templates, Inc. in its $52 million follow-on offering
  • Adaptimmune Therapeutics plc in its $100 million follow-on offering (investors' counsel)
  • Synlogic, Inc. in its $57.5 million follow-on offering and its $30 million registered direct offering 
  • Spero Therapeutics, Inc. in its $83.6 million IPO
  • WAVE Life Sciences Ltd. in its $102 million IPO
  • Achillion Pharmaceuticals, Inc. in its $141.4 million follow-on offering (underwriters' counsel)
  • TECO Energy in its $280.5 million public offering of common stock
  • Stemline Therapeutics, Inc. in its $30 million IPO
  • Recapitalization transaction of SofTech, Inc.
  • Atlantic Tele-Network in its $68 million public offering of common stock

Recognition & Awards

  • Recommended by The Legal 500 United States for M&A: Middle-Market (2017)
  • Named Lawyer of the Year in the area of Corporate Compliance Law (Boston) by Best Lawyers in America (2018)
  • Best Lawyers in America: Corporate Compliance Law, Corporate Governance Law, Corporate Law (2006 – 2021)
  • Named Lawyer of the Year in the area of Corporate Governance Law (Boston) by Best Lawyers in America (2017)

Involvement

  • Co-chair, Securities Law Committee, Boston Bar Association (2005 - 2007)
  • Member, Board of Overseers, Boys & Girls Club of Boston (2007 - 2013)
  • Trustee, South Kent School (2009-2014)
  • Elected member of Waban Area Council in Waban, Massachusetts (2013 - 2015)

Viewpoints

Mergers & Acquisitions Viewpoints Thumbnail Image

COVID-19 and Poison Pills: The Right Prescription?

April 30, 2020 | Advisory | By Matthew Gardella, Scott M. Stanton, Joshua B. Bergmann, David G. Conway

The coronavirus pandemic continues to have profound effects on the U.S. and global economies. Investor concerns about the impact of COVID-19 and government-imposed restrictions on individuals and businesses have led to unprecedented market volatility. Further material volatility is anticipated. In this environment, publicly traded companies may want to evaluate the adequacy of their corporate defenses to protect their stockholders from such predatory activities.
Read more
Viewpoint Thumbnail
A company’s past NOLs can be used to offset taxable income in future years, subject to certain limitations. For companies that have operated at a significant loss and expect to turn a profit in the foreseeable future, the value of their NOL carryforward may be one of their most valuable assets on their balance sheet.
Read more

News & Press

Press Release Thumbnail
Firm plays a key role in the largest health care acquisition to date in 2020.
Press Release Thumbnail
Best Lawyers named 85 Mintz attorneys to its 2018 list of The Best Lawyers in America. In addition, Mintz attorneys Matthew J. Gardella and Samuel M. Tony Starr were named “Lawyer of the Year” in their respective practice areas.
Best Lawyers named 73 Mintz attorneys to its 2017 list of The Best Lawyers in America. Mintz attorneys selected for inclusion in this year’s list span 44 practice areas. 
Best Lawyers named 73 Mintz attorneys to its 2017 list of The Best Lawyers in America. Mintz attorneys selected for inclusion in this year’s list span 44 practice areas. 

Events

Speaker
Jul
8
2020

Protecting Shareholder Value Today

Poison Pills and Takeover Defense Considerations During Pandemic Times

View the Webinar Recording

Speaker
Jun
3
2016